Request an invite

Elahere: which tox species, and why?

mirvetuximab soravtansine · FRα
Species
Cynomolgus monkey (general tox); rabbit for ocular tox; DM4 payload in monkey and mouse
“The monkey was demonstrated to be the most appropriate animal species for toxicological evaluation of MIRV based on FOLR1 gene sequence homology assessments, in vitro binding assays, and IHC analysis of FRα protein expression on fresh frozen tissue sections using MIRV.”
✓ VerifiedEMA assessment report, p. 49Source ↗
Why that species
Binds human and monkey FRα with similar affinity (98% homology); no binding to mouse or rat FRα; similar TCR staining
“MIRV (and M9346A) cross-reacts only with rhesus and cynomolgus monkey FRα, out of toxicological species.”
✓ VerifiedEMA assessment report, p. 41Source ↗
Surrogate molecule
No surrogate; clinical ADC in monkey and rabbit (ocular); free DM4 in non-GLP single-dose studies
“A 10-week GLP compliant repeat-dose toxicity study with mirvetuximab soravtansine was conducted in cynomolgus monkey using the clinical IV route of administration, and the payload DM4 was assessed in cynomolgus monkey in a non-GLP single IV dose toxicity study.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗

Same question, other ADCs

Adcetris

brentuximab vedotin · CD30
Rat and cynomolgus monkey (monkey the antigen-binding species)

Besponsa

inotuzumab ozogamicin · CD22
Rat and cynomolgus monkey (neither cross-reactive; target-independent toxicity only)

Datroway

datopotamab deruxtecan · Trop-2
Rat (non-binding) and cynomolgus monkey (relevant); DXd payload in rat and monkey

Decnupaz

pivekimab sunirine · CD123
Cynomolgus monkey (no CD123 cross-reactivity; off-target/payload toxicity) plus rat for FGN849 payload

Emrelis

telisotuzumab vedotin · c-Met
Cynomolgus monkey (relevant); rat non-binding (exploratory, MMAE-related effects)

Enhertu

fam-trastuzumab deruxtecan · HER2
Cynomolgus monkey (relevant) plus rat (non-binding species)

Kadcyla

ado-trastuzumab emtansine · HER2
Rat and cynomolgus monkey (monkey pharmacologically relevant; long-term studies in monkey)

Mylotarg

gemtuzumab ozogamicin · CD33
Rat and cynomolgus monkey (neither pharmacologically relevant; no CD33 cross-reactivity)

Padcev

enfortumab vedotin · Nectin-4
Rat and cynomolgus monkey

Polivy

polatuzumab vedotin · CD79b
Rat and cynomolgus monkey (monkey with clinical ADC plus monkey-CD79b surrogate ADC)

Tivdak

tisotumab vedotin · Tissue factor
Cynomolgus monkey only for ADC; rat and monkey for MMAE payload

Trodelvy

sacituzumab govitecan · Trop-2
Cynomolgus monkey only (mouse for target-independent toxicity only)

Zynlonta

loncastuximab tesirine · CD19
No pharmacologically relevant species; cynomolgus monkey (non-binding) for ADC; rat and dog for payload SG3199

Summary across all 14 ADCs →